EX-10.1




 Exhibit 10.1 

SECURITIES PURCHASE AGREEMENT 

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 24, 2022 by and among RAPT
Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). 

RECITALS 

A.    The Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from
securities registration afforded by the provisions of Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and Rule 506 of Regulation D (“Regulation D”), as promulgated by the U.S. Securities and
Exchange Commission (the “SEC”) under the 1933 Act; and 
 B.    The Investors wish to purchase from the
Company, and the Company wishes to sell and issue to the Investors, upon the terms and subject to the conditions stated in this Agreement, the pre-funded warrants to purchase shares of the Company’s
common stock, par value $0.0001 per share (the “Common Stock”), in the form attached hereto as Exhibit B (the “Pre-Funded Warrants”). 

C.    Contemporaneously with the sale of the Pre-Funded Warrants, the parties
hereto will execute and deliver a Registration Rights Agreement, in the form attached hereto as Exhibit C (the “Registration Rights Agreement”), pursuant to which the Company will agree to provide certain
registration rights in respect of the Warrant Shares (as defined below) under the 1933 Act, and the rules and regulations promulgated thereunder, and applicable state securities laws. 

In consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows: 
 1.    Definitions. For the purposes of this
Agreement, the following terms shall have the meanings set forth below: 
 “Affiliate” means, with respect to any Person,
any other Person which directly or indirectly through one or more intermediaries Controls, is controlled by, or is under common Control with, such Person. 

“Business Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general
transaction of business. 
 “Closing” has the meaning set forth in Section 3.1. 

“Closing Date” has the meaning set forth in Section 3.1. 

“Common Stock” has the meaning set forth in the recitals to this Agreement. 











 “Company’s Knowledge” means the actual knowledge of the executive
officers (as defined in Rule 405 under the 1933 Act) of the Company. 
 “Company Trials” has the meaning set forth in
Section 4.31. 
 “Control” (including the terms “controlling”, “controlled by” or “under
common control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

“Environmental Laws” has the meaning set forth in Section 4.16. 

“GAAP” has the meaning set forth in Section 4.18. 

“Governmental Entity” means any arbitrator, court, governmental body, regulatory body, administrative agency or other
authority, body or agency having jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or operations. 

“Governmental Licenses” means permits, licenses, approvals, consents and other authorizations. 

“Hazardous Materials” has the meaning set forth in Section 4.16. 

“Intellectual Property” has the meaning set forth in Section 4.15. 

“Investor Questionnaire” has the meaning set forth in Section 5.8. 

“Losses” has the meaning set forth in Section 8.2. 

“Material Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations,
prospects, condition (financial or otherwise) or business of the Company, (ii) the legality or enforceability of any of the Transaction Documents or (iii) the ability of the Company to perform its obligations under the Transaction
Documents. 
 “Material Contract” means any contract, instrument or other agreement to which the Company is a party or by
which it is bound which is material to the business of the Company, including those that have been filed or were required to have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(10) of
Regulation S-K. 
 “Nasdaq” means the Nasdaq Global Market. 

“Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint
stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 

“Pre-Funded Warrants” has the meaning set forth in the recitals to this Agreement.

 “Public Disclosure” has the meaning set forth in Section 9.7. 

  
 2 












 “Registration Rights Agreement” has the meaning set forth in the recitals
to this Agreement. 
 “Required Investors” has the meaning set forth in the Registration Rights Agreement. 

“SEC Filings” means the Company’s filings made pursuant to the 1934 Act. 

“Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the 1934 Act (but shall not be
deemed to include the location and/or reservation of borrowable shares of Common Stock). 
 “Subscription Amount” means, as
to an Investor, the aggregate amount to be paid for the Pre-Funded Warrants purchased hereunder as specified opposite such Investor’s name on Exhibit A attached hereto, under the column entitled
“Aggregate Purchase Price of Pre-Funded Warrants,” in U.S. Dollars and in immediately available funds. 

“Transfer Agent” has the meaning set forth in Section 7.6. 

“Transaction Documents” means this Agreement, the Pre-Funded Warrants and the
Registration Rights Agreement. 
 “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. 
 “1933 Act” has the meaning set forth in the recitals to this
Agreement. 
 “1934 Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and
regulations promulgated thereunder. 
 “1934 Act Regulations” means the rules and regulations of the SEC under the 1934
Act. 
 2.    Purchase and Sale of the Pre-Funded Warrants. On the
Closing Date, upon the terms and subject to the conditions set forth herein, the Company will issue and sell, and the Investors will purchase, severally and not jointly, Pre-Funded Warrants to purchase the
number of Warrant Shares set forth opposite the name of such Investor under the heading “Number of Warrant Shares Underlying Pre-Funded Warrant” on Exhibit A attached hereto. The purchase
price per Pre-Funded Warrant shall be $12.4999. The Pre-Funded Warrants shall have an exercise price equal to $0.0001 per Warrant Share. 

3.    Closing. 

3.1.    Upon the satisfaction of the conditions set forth in Section 6, the completion of the
purchase and sale of the Pre-Funded Warrants (the “Closing”) shall occur remotely via exchange of documents and signatures at a time (the “Closing Date”) to be agreed to by
the Company and the Investors but (i) in no event earlier than the second trading day after the date hereof and (ii) in no event later than the fifth trading day after the date hereof, and of which the Investors will be notified in advance
by the Company. 

  
 3 












 3.2.    On the Closing Date, each Investor shall deliver or cause to be
delivered to the Company the Subscription Amount via wire transfer of immediately available funds pursuant to the wire instructions delivered to such Investor by the Company on or prior to the Closing Date. 

3.3.    At or before the Closing, the Company shall deliver or cause to be delivered to each Investor a Pre-Funded Warrant, registered in the name of the Investor (or its nominee in accordance with its delivery instructions), to purchase up to the number of Warrant Shares set forth opposite the name of such Investor
under the heading “Number of Warrant Shares Underlying Pre-Funded Warrant” on Exhibit A attached hereto. 

4.    Representations and Warranties of the Company. The Company hereby represents and warrants to the Investors
that, except as otherwise described in the SEC Filings, which qualify these representations and warranties in their entirety: 

4.1.    Organization, Good Standing and Qualification. The Company has been duly organized and is validly existing
as a corporation in good standing under the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to conduct its business; and the Company is duly qualified as a foreign corporation to
transact business and is in good standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in
good standing would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Each subsidiary of the Company (each, a “Subsidiary” and, collectively, the “Subsidiaries”) has been duly
organized and is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization (to the extent the concept of “good standing” is applicable in each such jurisdiction), has corporate or similar
power and authority to own, lease and operate its properties and to conduct its business and is duly qualified to transact business and is in good standing in each jurisdiction in which such qualification is required (to the extent the concepts of
“qualification to transact business” and “good standing” are applicable in each such jurisdiction), whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or
to be in good standing would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Except as otherwise disclosed in the SEC filings, all of the issued and outstanding capital stock of each Subsidiary
has been duly authorized and validly issued, is fully paid and non assessable (to the extent such concepts are applicable in each such jurisdiction) and is owned by the Company, directly or through subsidiaries, free and clear of any security
interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock of any Subsidiary were issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The only
subsidiaries of the Company are the subsidiaries listed in Exhibit 21.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. 

4.2.    Authorization. The Company has the requisite corporate power and authority and has taken all requisite
corporate action necessary for, and no further action on the part of the Company, its officers, directors and stockholders is necessary for, (i) the authorization, execution and delivery of the Transaction Documents, (ii) the authorization
of the performance of all obligations of the Company hereunder or thereunder, and (iii) the 

  
 4 












 
authorization, reservation for issuance and delivery of the Warrant Shares. The Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally and to general equitable
principles. 
 4.3.    Capitalization. The authorized, issued and outstanding shares of capital stock of the
Company are as set forth in the Company’s most recent SEC Filing as of the date indicated therein (except for subsequent issuances, if any, pursuant to this Agreement, pursuant to reservations, agreements or employee benefit plans referred to
in the most recent SEC Filing or pursuant to the exercise of convertible securities or options referred to in the most recent SEC Filing). The outstanding shares of capital stock of the Company have been duly authorized and validly issued and are
fully paid and non assessable. None of the outstanding shares of capital stock of the Company were issued in violation of the preemptive or other similar rights of any securityholder of the Company. 

4.4.    Valid Issuance. The Warrant Shares have been duly and validly authorized and reserved for issuance and,
upon exercise of the Pre-Funded Warrants in accordance with their terms, including the payment of any exercise price therefor, will be validly issued, fully paid and nonassessable and will be free and clear of
all encumbrances and restrictions (other than those created by the Investors), except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws. The Common Stock conforms, in all material respects,
to all statements relating thereto contained in the SEC Filings and such description conforms in all material respects to the rights set forth in the instruments defining the same. No holder of Warrant Shares will be subject to personal liability
solely by reason of being such a holder. Assuming the accuracy of the representations and warranties of each Investor in Section 5 hereof, the Warrant Shares will be issued in compliance with applicable federal and state securities laws. 

4.5.    Consents. Subject to the accuracy of the representations and warranties of each Investor set forth in
Section 5 hereof, the execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Pre-Funded Warrants require no consent of, action by or in
respect of, or filing with, any Person, governmental body, agency, or official other than filings that have been made pursuant to applicable state securities laws and post-sale filings pursuant to applicable state and federal securities laws and the
rules and regulations of Nasdaq which the Company undertakes to file within the applicable time periods and other than the registration statement required to be filed by the Registration Rights Agreement. Subject to the accuracy of the
representations and warranties of each Investor set forth in Section 5 hereof, the Company has taken all action necessary to exempt (i) the issuance and sale of the Pre-Funded Warrants and
(ii) the other transactions contemplated by the Transaction Documents from the provisions of any stockholder rights plan or other “poison pill” arrangement, any anti-takeover, business combination or control share law or statute
binding on the Company or to which the Company or any of its assets and properties is subject that is or could reasonably be expected to become applicable to the Investors as a result of the transactions contemplated hereby, including without
limitation, the issuance of the Pre-Funded Warrants and the ownership, disposition or voting of the Warrant Shares by the Investors or the exercise of any right granted to the Investors pursuant to this
Agreement or the other Transaction Documents. 

  
 5 












 4.6.    Delivery of SEC Filings; Business. The Company has made
available to the Investors through the EDGAR system, true and complete copies of the SEC Filings. The Company has made all filings required to be made pursuant to the 1934 Act. The Company is engaged in all material respects only in the business
described in the SEC Filings and the SEC Filings contain a complete and accurate description in all material respects of the business of the Company. 

4.7.    Use of Proceeds. The net proceeds of the sale of the Pre-Funded
Warrants hereunder shall be used by the Company for working capital and general corporate purposes. 
 4.8.    No
Material Adverse Change. Since March 31, 2022, there has not been: 
 (i)    any change in the assets,
liabilities, financial condition or operating results of the Company from that reflected in the financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2022, except for changes in the ordinary course of business which have not had and would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; 

(ii)    any declaration or payment by the Company of any dividend, or any authorization or payment by the Company of any
distribution, on any of the capital stock of the Company, or any redemption or repurchase by the Company of any securities of the Company; 

(iii)    any material damage, destruction or loss, whether or not covered by insurance, to any assets or properties of
the Company; 
 (iv)    any waiver, not in the ordinary course of business, by the Company of a material right or of a
material debt owed to it; 
 (v)    any satisfaction or discharge of any lien, claim or encumbrance or payment of any
obligation by the Company, except in the ordinary course of business and which is not material to the assets, properties, financial condition, operating results or business of the Company (as such business is presently conducted); 

(vi)    any change or amendment to the Company’s Certificate of Incorporation or Bylaws, or material change to any
material contract or arrangement by which the Company or is bound or to which any of its assets or properties is subject; 

(vii)    any material labor difficulties or, to the Company’s Knowledge, labor union organizing activities with
respect to employees of the Company; 
 (viii)    any material transaction entered into by the Company other than in
the ordinary course of business; 

  
 6 












 (ix)    the loss of the services of any key employee, or material
change in the composition or duties of the senior management of the Company; or 
 (x)    any other event or condition
of any character that has had or would reasonably be expected to have a Material Adverse Effect. 
 4.9.    SEC
Filings. 
 (a)    At the time of filing thereof, the SEC Filings complied as to form in all material respects with
the requirements of the 1933 Act or 1934 Act, as applicable, and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in
the light of the circumstances under which they were made, not misleading. 
 (b)    Each prospectus filed pursuant to
Rule 424(b) under the 1933 Act, as of its issue date and as of the closing of any sale of securities pursuant thereto, did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. 

4.10.    No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction
Documents by the Company and the issuance and sale of the Pre-Funded Warrants in accordance with the provisions thereof will not, (i) conflict with or result in a breach or violation of (a) any of
the terms and provisions of, or constitute a default under, the Company’s Certificate of Incorporation or Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investors through the
EDGAR system), or (b) assuming the accuracy of the representations and warranties in Section 5, any applicable statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction
over the Company, or any of its assets or properties, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien, encumbrance or other
adverse claim upon any of the properties or assets of the Company or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract except, with respect to
clauses (i)(b) and (ii), for such violations, conflicts or defaults as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. This Section does not relate to matters with respect to tax status, which
are the subject of Section 4.11, employee relations and labor matters, which are the subject of Section 4.14, and environmental laws, which are the subject of Section 4.16. 

4.11.    Tax Matters. All United States federal income tax returns of the Company and its subsidiaries required by
law to be filed by them (taking into account any timely requested extensions thereof) have been filed and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have
been or will be promptly taken and as to which adequate reserves have been provided. The Company and its subsidiaries have filed all other tax returns that are required to have been filed by them pursuant to applicable foreign, state, local or other
law except insofar as the failure to 

  
 7 












 
file such returns would not reasonably be expected to result in a Material Adverse Effect, and has paid all material taxes due pursuant to such returns or pursuant to any assessment received by
the Company and its subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by the Company. The charges, accruals and reserves on the books of the Company in respect
of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or re-assessments for additional income tax for any years not finally determined, except to
the extent of any inadequacy that would not reasonably be expected to result in a Material Adverse Effect. 

4.12.    Title to Properties. The Company and its subsidiaries have good and marketable title to all real property
owned by them and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (i) are described in the SEC
Filings or, (ii) do not, singly or in the aggregate, materially adversely affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company or any of its subsidiaries;
and all of the leases and subleases material to the business of the Company and its subsidiaries, considered as one enterprise, and under which the Company or any of its subsidiaries holds properties described in the SEC Filings, are in full force
and effect, and neither the Company nor any such subsidiary has any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any subsidiary under any of the leases or subleases mentioned
above, or affecting or questioning the rights of the Company or such subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease, except to the extent that any such failure to be in full force and
effect or any such claim could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. 

4.13.    Licenses and Permits. The Company and its subsidiaries possess such Governmental Licenses issued by the
appropriate Governmental Entities necessary to conduct the business now operated by them, except where the failure so to possess would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. The Company and
its subsidiaries are in compliance with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. All of the
Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, reasonably be
expected to result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the
subject of an unfavorable decision, ruling or finding, would reasonably be expected to result in a Material Adverse Effect. 

4.14.    Labor Matters. No labor dispute with the employees of the Company or any of its subsidiaries exists or, to
the Company’s Knowledge, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or any subsidiary’s principal suppliers, manufacturers, customers or contractors, which, in
either case, would reasonably be expected to result in a Material Adverse Effect. 

  
 8 












 4.15.    Intellectual Property. Except as described in the SEC
Filings or would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect, (i) the Company and its subsidiaries own, possess or can promptly obtain on commercially reasonable terms a valid and enforceable
license to use, all patents, patent rights, licenses, inventions, copyrights, technology, software, databases, know how (including any trade secrets and any other unpatented and/or unpatentable proprietary or confidential information, systems or
procedures), trademarks, service marks, trade names, trade dress, domain names and other source identifiers, and any other similar intellectual property or proprietary rights in any jurisdiction throughout the world (including any and all issuances
and registrations and applications for issuance or registration of, and all goodwill associated with, any of the foregoing, as applicable) (collectively, “Intellectual Property”) used or held for use in, or otherwise necessary to, the
conduct of the business as now operated by them and as proposed to be operated in the SEC Filings; (ii) to the Company’s Knowledge, the Company’s and its subsidiaries’ conduct of their business does not infringe, misappropriate
or otherwise violate, and has not infringed, misappropriated or otherwise violated, asserted rights of any others with respect to any Intellectual Property (it being understood that the foregoing representation and warranty is made without giving
effect to any exemption under applicable law to which the Company may be entitled (e.g., 35 U.S.C. Section 271(e)(1))); (iii) neither the Company nor any of its subsidiaries has received any notice or is otherwise aware of, (A) any pending
or threatened action, suit, proceeding or claim by any third party against the Company or any of its subsidiaries (x) alleging that the Company or any of its subsidiaries has infringed, misappropriated or otherwise violated any Intellectual
Property, (y) challenging the ownership, validity, enforceability or scope of any Intellectual Property owned by or licensed to the Company or any of its subsidiaries or (z) challenging the Company’s or any of its subsidiaries’
rights in or to any of the Intellectual Property or (B) any facts that would form a reasonable basis for any such action, suit, proceeding or claim; (iv) to the Company’s Knowledge, the Intellectual Property of the Company and its
subsidiaries has not been infringed, misappropriated or otherwise violated by any third party; (v) all Intellectual Property owned by the Company or any of its subsidiaries is owned solely and exclusively by the Company or such subsidiaries and
the Company and its subsidiaries own such Intellectual Property and hold all of their rights under all Intellectual Property licensed to them, in each case, free and clear of all liens, encumbrances, defects or other restrictions; and (vi) the
Company and its subsidiaries have taken reasonable steps in accordance with normal industry standards and practices to maintain the confidentiality of all Intellectual Property of the Company and its subsidiaries the value of which to the Company or
any of its subsidiaries is contingent upon maintaining the confidentiality thereof and, to the Company’s Knowledge, no such Intellectual Property has been disclosed other than to employees, representatives and agents of the Company or any of
its subsidiaries, all of whom are bound by written and enforceable confidentiality agreements. 

4.16.    Environmental Matters. Except as described in the SEC Filings or would not, singly or in the aggregate,
result in a Material Adverse Effect, (i) neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or
administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water,
groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened 

  
 9 












 
release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively,
“Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”), (ii) the Company and its subsidiaries
have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements, (iii) there are no pending or, to the Company’s Knowledge, threatened administrative,
regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigations or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (iv) to the
Company’s Knowledge, there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party
or Governmental Entity, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws. 

4.17.    Legal Proceedings. Except as disclosed in the SEC Filings, there is no action, suit, proceeding, inquiry
or investigation before or brought by any Governmental Entity now pending or, to the Company’s Knowledge, threatened, against or affecting the Company or any of its subsidiaries, which would reasonably be expected to result in a Material
Adverse Effect, or which would reasonably be expected to materially and adversely affect their respective properties or assets or the consummation of the transactions contemplated in the Transaction Documents or the performance by the Company of its
obligations thereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such subsidiary is a party or of which any of their respective properties or assets is the subject which are not described in the
SEC Filings, including ordinary routine litigation incidental to the business, would not reasonably be expected to result in a Material Adverse Effect. 

4.18.    Financial Statements. The financial statements included in each SEC Filing, together with the related
schedules and notes, present fairly in all material respects the financial position of the Company and its consolidated subsidiaries at the dates indicated and the statement of operations, stockholders’ equity and cash flows of the Company and
its consolidated subsidiaries for the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods involved
(except as may be disclosed therein or in the notes thereto, and except that the unaudited financial statements may not contain all footnotes required by GAAP, and, in the case of quarterly financial statements, as permitted by Form 10-Q under the 1934 Act). The Company has not incurred any liabilities, contingent or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices
since the date of such financial statements, none of which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect. 

4.19.    Insurance Coverage. The Company and its subsidiaries carry or are entitled to the benefits of insurance,
with financially sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute engaged in the same or similar business, and all such insurance is in full force and effect. The
Company has no reason to believe that it or any of its subsidiaries will not be able (A) to renew its existing insurance coverage as and when such policies expire or (B) to obtain comparable


  
 10 












 
coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. Neither of the
Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied. 

4.20.    Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq
continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor
to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq. 

4.21.    Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction
Documents, any valid right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company. No Investor
shall have any obligation with respect to any fees, or with respect to any claims made by or on behalf of other Persons for fees, in each case of the type contemplated by this Section 4.21 that may be due in connection with the transactions
contemplated by this Agreement or the Transaction Documents. 
 4.22.    No Directed Selling Efforts or General
Solicitation. Neither the Company nor any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or sale of any of the Pre-Funded Warrants. 
 4.23.    No Integrated Offering. Neither the Company
nor any Person acting on its behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on
Section 4(a)(2) for the exemption from registration for the transactions contemplated hereby or would require registration of the Warrant Shares under the 1933 Act. 

4.24.    Private Placement. Assuming the accuracy of the representations and warranties of the Investors set forth
in Section 5, the offer and sale of the Pre-Funded Warrants to the Investors and the exercise of the Pre-Funded Warrants as contemplated hereby are exempt from the
registration requirements of the 1933 Act. 
 4.25.    Questionable Payments. Neither the Company
nor, to the Company’s Knowledge, any of the Company’s directors, officers, employees, agents or other Persons acting on behalf of the Company, has on behalf of the Company: (a) used any corporate funds for unlawful contributions,
gifts, entertainment or other unlawful expenses relating to political activity; (b) made any direct or indirect unlawful payments to any governmental officials or employees from corporate funds; (c) established or maintained any unlawful
or unrecorded fund of corporate monies or other assets which is in violation of law; (d) made any false or fictitious entries on the books and records of the Company; or (e) made any unlawful bribe, rebate, payoff, influence payment,
kickback or other unlawful payment of any nature. 

  
 11 












 4.26.    Transactions with Affiliates. None of the executive
officers or directors of the Company and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company (other than as holders of stock options, and for services as employees, officers
and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director
or such employee or, to the Company’s Knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. 

4.27.    Internal Controls. The Company and its subsidiaries, on a consolidated basis, maintain a system of
effective internal control over financial reporting (as defined under Rule 13-a15 and 15d-15 under the 1934 Act Regulations) and a system of internal accounting controls
each designed to provide reasonable assurances that (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; (D) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in the SEC Filings, since the end of the Company’s most recent audited fiscal year, there has been
(1) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (2) no change in the Company’s internal control over financial reporting that has materially affected, or is
reasonably likely to materially and adversely affect, the Company’s internal control over financial reporting. 

4.28.    Disclosures. Neither the Company nor any Person acting on its behalf has provided the Investors or their
agents or counsel with any information that constitutes or would reasonably be expected to constitute material nonpublic information concerning the Company or its subsidiaries, other than with respect to the transactions contemplated hereby, which
will be disclosed in the Public Disclosure (as defined below). The SEC Filings do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein, in light of the
circumstances under which they were made, not misleading. The Company understands and confirms that the Investors will rely on the foregoing representations in effecting transactions in securities of the Company. 

4.29.    Required Filings. Except for the transactions contemplated by the Transaction Documents, including the
acquisition of the Pre-Funded Warrants contemplated hereby, no event or circumstance has occurred or information exists with respect to the Company or its business, properties, operations or financial
condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed (assuming for this purpose that the SEC Filings are being incorporated by
reference into an effective registration statement filed by the Company under the 1933 Act). 
 4.30.    Investment
Company. The Company is not required to be registered as, and is not an Affiliate of, and immediately following the Closing will not be required to register as, an “investment company” within the meaning of the Investment Company Act
of 1940, as amended. 

  
 12 












 4.31.    Tests and Preclinical and Clinical Trials. All clinical
and preclinical tests and trials conducted by or on behalf of the Company, including any such studies and trials that are described in or referred to in the SEC Filings (the “Company Trials”) were and, if still pending, are being conducted
in accordance with standard medical and scientific research standards and procedures; current Good Clinical Practices and Good Laboratory Practices, where applicable; and all applicable laws, rules, and regulations of any applicable regulatory
authority, including without limitation the Federal Food, Drug, and Cosmetic Act and the regulations set forth at 21 C.F.R. Parts 50, 54, 56, 58 and 312. The descriptions of the results of the Company Trials contained in the SEC Filings are accurate
and complete in all material respects and fairly present the data derived therefrom. The Company has no knowledge of any other tests the results of which are inconsistent with or otherwise call into question the results described or referred to in
the SEC Filings. The Company has not received any written notices or other correspondence from any regulatory authority requiring the termination, suspension or material modification of any preclinical tests or clinical trials. 

4.32.    Manipulation of Price. The Company has not, and, to the Company’s Knowledge, no Person acting on
its behalf has taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the
Pre-Funded Warrants. 
 4.33.    Bad Actor Disqualification. None of the
Company, any predecessor or affiliated issuer of the Company nor, to the Company’s Knowledge, any director or executive officer of the Company or any promoter connected with the Company in any capacity, is subject to any of the “bad
actor” disqualifications within the meaning of Rule 506(d) under the 1933 Act, except for a disqualification event covered by Rule 506(d)(2) or (d)(3). 

4.34.    Absence of Violations, Defaults and Conflicts. Neither the Company nor any of its subsidiaries is
(i) in violation of its charter, by-laws or similar organizational document, (ii) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any
Material Contract, except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or (iii) in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental
Entity, except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. 

4.35.    Healthcare Laws. The Company has operated at all times and is currently in compliance in all material
respects with all applicable statutes, rules and regulations of the U.S. Food and Drug Administration and applicable foreign regulatory authorities, including the European Medicines Agency and the UK Medicines and Healthcare products Regulatory
Agency, including, without limitation, (A) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.) and the regulations promulgated thereunder; (B) all healthcare related fraud and abuse laws, including, without
limitation, the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)); the civil False Claims Act (31 U.S.C. §§ 3729 et seq.); the criminal False Claims Law (42 U.S.C. § 1320a-7b(a)); the civil monetary penalties law (42 U.S.C. § 1320a-7a); the exclusion law (42 U.S.C. § 1320a-7); the Physician
Payments Sunshine Act (42 U.S.C. § 1320a-7h); all 

  
 13 












 
criminal laws relating to healthcare fraud and abuse, including, but not limited to 18 U.S.C. Sections 286, 287, 1035, 1347 and 1349; the healthcare fraud criminal provisions under the U.S.
Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. §§ 1320d et seq.), the Medicare statute (Title XVIII of the Social Security Act) and the Medicaid statute (Title XIX of the Social Security Act);
(C) the patient privacy, data security and breach notification provisions under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. §§ 17921 et seq.); and (D) licensure,
quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies (collectively, as amended, the “Healthcare Laws”). The Company is not a party to and does not have any ongoing
reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement with or imposed by any Governmental Entity.
Additionally, neither the Company, nor any of its employees, officers, directors or agents, is or has been excluded, suspended, debarred or is otherwise ineligible from participation in any U.S. state or federal healthcare program or human clinical
research, or is subject to a governmental inquiry, investigation, proceeding or other similar action that could reasonably be expected to result in such exclusion, suspension or debarment. Except as described in the SEC Filings, the Company
(x) has not received any Form 483, notice of adverse finding, warning letter, untitled letter or other written correspondence, or any other notice from any Governmental Entity alleging or asserting noncompliance with any Healthcare Laws or the
terms of any Governmental Licenses; (y) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation or arbitration from any Governmental Entity or third party alleging that any product operation or
activity is in violation of any Healthcare Laws or Governmental Licenses and (z) has no knowledge that any such Governmental Entity or third party is considering any such claim, action, suit, proceeding, hearing, enforcement, investigation or
arbitration. The Company has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments required by any Healthcare Laws or Governmental Licenses;
all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct and not misleading on the date filed; and the Company is not aware of any reasonable basis for any
material liability with respect thereto. The Company and the Company’s officers, employees and agents have not made any untrue statement of material fact or fraudulent statement to any Governmental Entity or failed to disclose a material fact
required to be disclosed to any Governmental Entity. 
 4.36.    Money Laundering Laws. The operations of the
Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering
statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and
no action, suit or proceeding by or before any Governmental Entity involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the Company’s Knowledge, threatened. 

4.37.    OFAC. None of the Company, any of its subsidiaries or, to the Company’s Knowledge, any director,
officer, agent, employee, affiliate or representative of the 

  
 14 












 
Company or any of its subsidiaries is a Person currently the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S.
Department of the Treasury’s Office of Foreign Assets Control (“OFAC”), the United Nations Security Council (“UNSC”), the European Union, Her Majesty’s Treasury (“HMT”), or other relevant sanctions authority
(collectively, “Sanctions”), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the Shares, or lend,
contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund or facilitate any activities of or business with any Person, or in any country or territory, that, at the time of such funding
or facilitating, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. 

4.38.    Cybersecurity. Except as described in the SEC Filings, (A) to the Company’s Knowledge, there has
been no security breach or incident, unauthorized access or disclosure, or other compromise of or relating to the Company or its subsidiaries’ information technology assets and equipment and computers, systems, networks, hardware, software,
websites, applications, data and databases (including all data and information of their respective customers, employees, suppliers, vendors and any third party data collected, maintained, processed or stored by the Company and its subsidiaries, and
any such data collected, maintained, processed or stored by third parties on behalf of the Company and its subsidiaries), equipment or technology (collectively, “IT Systems and Data”); (B) the Company’s IT Systems and Data are
adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan
horses, time bombs, malware and other corruptants; (C) neither the Company nor its subsidiaries have been notified of, and each of them have no knowledge of any event or condition that could result in, any security breach or incident,
unauthorized access or disclosure or other compromise to their IT Systems and Data; (D) the Company and its subsidiaries have implemented and maintained appropriate controls, policies, procedures, and technological safeguards, including backup
and disaster recovery technology, to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of their IT Systems and Data reasonably consistent with industry standards and
practices or as required by applicable regulatory standards and (E) the Company and its subsidiaries are presently, and have been, in material compliance with all applicable laws and statutes and all judgments, orders, rules and regulations of
any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of their IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use,
access, misappropriation or modification. 
 5.    Representations and Warranties of the Investors. Each of the
Investors hereby severally, and not jointly, represents and warrants to the Company that: 
 5.1.    Organization and
Existence. Such Investor is a duly incorporated or organized and validly existing corporation, limited partnership or limited liability company and has all requisite corporate, partnership or limited liability company power and authority to
enter into and consummate the transactions contemplated by the Transaction Documents and to carry out its obligations hereunder and thereunder, and to invest in the Pre-Funded Warrants pursuant to this
Agreement, and is in good standing under the laws of the jurisdiction of its incorporation or organization. 

  
 15 












 5.2.    Authorization. The execution, delivery and performance by
such Investor of the Transaction Documents to which such Investor is a party have been duly authorized and each has been duly executed and when delivered will constitute the valid and legally binding obligation of such Investor, enforceable against
such Investor in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally. 

5.3.    Purchase Entirely for Own Account. The Pre-Funded Warrants to be
received by such Investor hereunder will be acquired for such Investor’s own account, not as nominee or agent, for the purpose of investment and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and
such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the 1933 Act without prejudice, however, to such Investor’s right at all times to sell or otherwise dispose of
all or any part of such Pre-Funded Warrants in compliance with applicable federal and state securities laws. The Pre-Funded Warrants are being purchased by such Investor
in the ordinary course of its business. Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Pre-Funded Warrants for any period of time. Such Investor is not a
broker-dealer registered with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered. 

5.4.    Investment Experience. Such Investor acknowledges that it can bear the economic risk and complete loss of
its investment in the Pre-Funded Warrants and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby.

 5.5.    Disclosure of Information. Such Investor has had an opportunity to receive, review and understand all
information related to the Company requested by such Investor and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the
Pre-Funded Warrants, and has conducted and completed such Investor’s own independent due diligence. Such Investor acknowledges that copies of the SEC Filings are available on the EDGAR system. Based on
the information such Investor has deemed appropriate, it has independently made its own analysis and decision to enter into the Transaction Documents. Such Investor is relying exclusively on its own sources of information, investment analysis and
due diligence (including professional advice it deems appropriate) with respect to the execution, delivery and performance of the Transaction Documents, the Pre-Funded Warrants and the business, condition
(financial and otherwise), management, operations, properties and prospects of the Company, including but not limited to all business, legal, regulatory, accounting, credit and tax matters. Neither such inquiries nor any other due diligence
investigation conducted by such Investor shall modify, limit or otherwise affect such Investor’s right to rely on the Company’s representations and warranties contained in this Agreement. 

  
 16 












 5.6.    Restricted Securities. Such Investor understands that the
Pre-Funded Warrants and Warrant Shares are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not
involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain limited circumstances. 

5.7.    Legends. It is understood that, except as provided below, certificates or book-entry records evidencing the
Pre-Funded Warrants and Warrant Shares may bear the following or any similar legend: 

“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES
ACT OF 1933, AS AMENDED, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED.” 
 If required by the authorities of any state in connection with the issuance or sale of the Pre-Funded Warrants and Warrant Shares, the legend required by such state authority. 

5.8.    Accredited Investor. Such Investor is an “accredited investor” within the meaning of Rule 501
under the 1933 Act and has executed and delivered to the Company a questionnaire in substantially the form attached hereto as Exhibit D (the “Investor Questionnaire”), which such Investor represents and warrants is true,
correct and complete. Such investor is a sophisticated institutional investor with sufficient knowledge and experience in investing in private equity transactions to properly evaluate the risks and merits of its purchase of the Pre-Funded Warrants. Such Investor has determined based on its own independent review and such professional advice as it deems appropriate that its purchase of the Pre-Funded
Warrants and participation in the transactions contemplated by the Transaction Documents (i) are fully consistent with its financial needs, objectives and condition, (ii) comply and are fully consistent with all investment policies,
guidelines and other restrictions applicable to such Investor, (iii) have been duly authorized and approved by all necessary action, (iv) do not and will not violate or constitute a default under such Investor’s charter, bylaws or
other constituent document or under any law, rule, regulation, agreement or other obligation by which such Investor is bound and (v) are a fit, proper and suitable investment for such Investor, notwithstanding the substantial risks inherent in
investing in or holding the Pre-Funded Warrants. Such Investor understands that the Pre-Funded Warrants are being offered and sold to it in reliance upon specific
exemptions from the registration requirements of the Securities Act and state securities laws, and that the Company is relying upon the truth and accuracy of, and 

  
 17 












 
such Investor’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Investor set forth herein in order to determine the availability of
such exemptions and the eligibility of such Investor to acquire the Pre-Funded Warrants. 

5.9.    Ownership of Capital Stock. As of the date hereof, such Investor and its affiliates beneficially own such
shares of capital stock of the Company as set forth in the Investor Questionnaire. 
 5.10.    No General
Solicitation. Such Investor did not learn of the investment in the Pre-Funded Warrants as a result of any general or public solicitation or general advertising, or publicly disseminated advertisements or
sales literature, including (a) any advertisement, article, notice or other communication published in any newspaper, magazine, website, or similar media, or broadcast over television or radio, or (b) any seminar or meeting to which such
Investor was invited by any of the foregoing means of communications. 
 5.11.    Brokers and Finders. No Person
will have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement
or understanding entered into by or on behalf of such Investor. 
 5.12.    Short Sales and Confidentiality Prior to
the Date Hereof. Other than consummating the transactions contemplated hereunder, such Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with such Investor, directly or indirectly executed any purchases or
sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Investor was first contacted by the Company or any other Person regarding the transactions contemplated hereby and ending
immediately prior to the date hereof. Notwithstanding the foregoing, in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor’s assets and the
portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Investor’s assets, the representation set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Pre-Funded Warrants covered by this Agreement. Other than to other Persons party to this Agreement and other than to such
Person’s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative
tasks and services and other than as may be required by law, such Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to
effect Short Sales or similar transactions in the future. 
 5.13.     No Government Recommendation or Approval.
Such Investor understands that no United States federal or state agency, or similar agency of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase of the Pre-Funded Warrants. 

  
 18 












 5.14.    No Conflicts. The execution, delivery and performance by
such Investor of the Transaction Documents and the consummation by such Investor of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Investor or (ii) conflict with,
or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which
such Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Investor, except in the case of clauses (ii) and (iii) above,
for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Investor to perform its obligations hereunder. 

5.15.    Residency. Such Investor is a resident of the jurisdiction specified below its address on the Schedule of
Investors in Exhibit A hereto. 
 5.16.    No Legal, Tax or Investment Advice. Such Investor understands
that nothing in this Agreement or any other materials presented by or on behalf of the Company to such Investor in connection with the purchase of the Pre-Funded Warrants constitutes legal, tax or investment
advice. Such Investor has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Pre-Funded Warrants. 

6.    Conditions to Closing. 

6.1.    Conditions to the Investors’ Obligations. The obligation of each Investor to purchase Pre-Funded Warrants at the Closing is subject to the fulfillment to such Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Investor (as to
itself only): 
 (a)    The representations and warranties made by the Company in Section 4 hereof shall be true
and correct in all material respects (except for those representations and warranties which are qualified as to materiality or by Material Adverse Effect, in which case such representations and warranties shall be true and correct in all respects)
as of the date hereof and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date. The
Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date. 

(b)    The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for
consummation of the purchase and sale of the Pre-Funded Warrants and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect. 

(c)    The Company shall have executed and delivered the Registration Rights Agreement. 

  
 19 












 (d)    The Company shall have filed with Nasdaq a Notification Form:
Listing of Additional Shares for the listing of the Warrant Shares, a copy of which shall have been provided to the Investors. 

(e)    No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate,
including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the consummation of the
transactions contemplated hereby or in the other Transaction Documents. 
 (f)    The Company shall have delivered a
Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a), (b), (d), (e) and
(i) of this Section 6.1. 
 (g)    The Company shall have delivered a Certificate, executed on behalf of the
Company by its Secretary, dated as of the Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the
Pre-Funded Warrants, certifying the current versions of the Certificate of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons signing the Transaction Documents
and related documents on behalf of the Company. 
 (h)    a legal opinion of Cooley LLP, legal counsel to the Company,
in a form reasonably acceptable to the Investors. 
 (i)    No stop order or suspension of trading shall have been
imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect to public trading in the Common Stock. 

6.2.    Conditions to Obligations of the Company. The Company’s obligation to sell and issue the Pre-Funded Warrants at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company: 

(a)    The representations and warranties made by the Investors in Section 5 hereof shall be true and correct in all
material respects (except for those representations and warranties which are qualified as to materiality, in which case such representations and warranties shall be true and correct in all respects) as of the date hereof and on the Closing Date. The
Investors shall have performed in all material respects all obligations and covenants herein required to be performed by them on or prior to the Closing Date. 

(b)    The Investors shall have executed and delivered the Registration Rights Agreement and each Investor Questionnaire.

 (c)    Any Investor purchasing Pre-Funded Warrants at the Closing shall have
paid in full its Subscription Amount to the Company. 

  
 20 












 6.3.    Termination of Obligations to Effect Closing; Effects.

 (a)    The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing
shall terminate as follows: 
 (i)    Upon the mutual written consent of the Company and Investors that agreed to
purchase a majority of the Pre-Funded Warrants to be issued and sold pursuant to this Agreement; 

(ii)    By the Company if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment,
and shall not have been waived by the Company; 
 (iii)    By an Investor (with respect to itself only) if any of the
conditions set forth in Section 6.1 shall have become incapable of fulfillment, and shall not have been waived by the Investor; or 

(iv)    By either the Company or any Investor (with respect to itself only) if the Closing has not occurred on or prior
to the fifth trading day following the date of this Agreement; 
 provided, however, that, except in the case of clause (i) above, the party seeking to
terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents if such breach has resulted in the
circumstances giving rise to such party’s seeking to terminate its obligation to effect the Closing. 
 (b)    In
the event of termination by the Company or any Investor of its obligations to effect the Closing pursuant to this Section 6.3, written notice thereof shall be given to the other Investors by the Company and the other Investors shall have the
right to terminate their obligations to effect the Closing upon written notice to the Company and the other Investors. Nothing in this Section 6.3 shall be deemed to release any party from any liability for any breach by such party of the terms
and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. 

7.    Covenants and Agreements of the Company and the Investors. 

7.1.    Nasdaq Listing. The Company shall promptly secure the listing of all of the Warrant Shares on Nasdaq and
shall pay all fees and expenses in connection with satisfying its obligations under this Section 7.1. The Company will use commercially reasonable efforts to continue the listing and trading of its Common Stock on Nasdaq and, in accordance,
therewith, will use commercially reasonable efforts to comply with the Company’s reporting, filing and other obligations under the bylaws or rules of such market or exchange, as applicable. 

7.2.    Removal of Legends. In connection with any sale or disposition of the Warrant Shares by an Investor
pursuant to Rule 144 or pursuant to any other exemption under the 1933 Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor, the
Company 

  
 21 












 
shall cause the transfer agent for the Common Stock (the “Transfer Agent”) to remove any restrictive legends related to the book entry account holding such Warrant Shares and make a
new, unlegended entry for such book entry Warrant Shares sold or disposed of without restrictive legends within two trading days of receipt of such request, provided that the Company has received customary representations and other documentation
reasonably acceptable to the Company in connection therewith. Subject to receipt by the Company of customary representations and other documentation reasonably acceptable to the Company in connection therewith, upon the earlier of such time as the
Warrant Shares (i) have been registered for resale pursuant to an effective registration statement, (ii) such time as the Warrant Shares have been or are about to be sold pursuant to Rule 144, or (iii) are eligible for resale
under Rule 144(b)(1) or any successor provision, the Company shall (A) deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry Warrant Shares, and (B) cause its
counsel to deliver to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the 1933 Act. The Company shall be responsible for the fees of its Transfer Agent and all DTC
fees associated with such issuance. 
 Each Investor, severally and not jointly with the other Investors, agrees with the Company (i) that such
Investor will sell any Warrant Shares only pursuant to either the registration requirements of the 1933 Act, including any applicable prospectus delivery requirements, or an exemption therefrom, (ii) that if Warrant Shares are sold pursuant to
a registration statement, they will be sold in compliance with the plan of distribution set forth therein and (iii) that if, after the effective date of the registration statement covering the resale of the Warrant Shares, such registration
statement ceases to be effective and the Company has provided notice to such Investor to that effect, such Investor will sell Warrant Shares only in compliance with an exemption from the registration requirements of the 1933 Act. 

7.3.    Subsequent Equity Sales. The Company shall not, and shall use its commercially reasonable efforts to ensure
that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the 1933 Act) that will be integrated with the offer or sale of the Pre-Funded Warrants in a manner that would require the registration under the 1933 Act of the sale of the Pre-Funded Warrants to the Investors, or that will be integrated with
the offer or sale of the Pre-Funded Warrants for purposes of the rules and regulations of any trading market such that it would require stockholder approval prior to the closing of such other transaction
unless stockholder approval is obtained before the closing of such subsequent transaction. 
 7.4.    Short Sales and
Confidentiality After the Date Hereof. Each Investor covenants that neither it nor any Affiliates acting on its behalf or pursuant to any understanding with it will execute any Short Sales during the period from the date hereof until the earlier
of such time as (i) after the transactions contemplated by this Agreement are first publicly announced or (ii) this Agreement is terminated in full. Each Investor covenants that until such time as the transactions contemplated by this
Agreement are publicly disclosed by the Company, such Investor will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Each Investor understands and
acknowledges that the SEC currently takes the position that coverage of short sales of shares of the Common Stock “against the box” prior to effectiveness of a resale 

  
 22 












 
registration statement with securities included in such registration statement would be a violation of Section 5 of the 1933 Act, as set forth in Item 239.10 of the 1933 Act Rules Compliance
and Disclosure Interpretations compiled by the Office of Chief Counsel, Division of Corporation Finance. 

8.    Survival and Indemnification. 

8.1.    Survival. The representations, warranties, covenants and agreements contained in this Agreement shall
survive the Closing of the transactions contemplated by this Agreement for the applicable statute of limitations. 

8.2.    Indemnification. The Company agrees to indemnify and hold harmless each Investor and its Affiliates and
their respective directors, officers, trustees, members, managers, employees and agents, and their respective successors and assigns, from and against any and all losses, claims, damages, liabilities and expenses (including without limitation
reasonable and documented attorney fees and disbursements and other documented out-of-pocket expenses reasonably incurred in connection with investigating, preparing or
defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, “Losses”) to which such Person may become subject as a result of any breach of representation, warranty, covenant or
agreement made by or to be performed on the part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts have been finally
judicially determined not to have resulted from such Person’s fraud or willful misconduct. 
 8.3.    Conduct of
Indemnification Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such
indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to
participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party
shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists
between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the
indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the
indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying
party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent
of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or
plaintiff to 

  
 23 












 
such indemnified party of a release from all liability in respect of such claim or litigation. No indemnified party will, except with the consent of the indemnifying party, which consent shall
not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement. 

9.    Miscellaneous. 

9.1.    Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written
consent of the Company or the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate its duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its Pre-Funded Warrants in a transaction complying with applicable securities laws without the prior written consent of the Company or the other Investors, provided such assignee agrees in writing to be bound by the
provisions hereof that apply to Investors. The provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Without limiting the generality of the foregoing, in the
event that the Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock is converted into the equity securities of another Person, from and after the effective time of such
transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be deemed to refer to such Person and the term
“Pre-Funded Warrants” shall be deemed to refer to the securities received by the Investors in connection with such transaction. Nothing in this Agreement, express or implied, is intended to confer
upon any party other than the parties hereto or their respective permitted successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

9.2.    Counterparts; Faxes; E-mail. This Agreement may be executed in one
or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile or e-mail, which shall
be deemed an original. 
 9.3.    Titles and Subtitles. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement. 

9.4.    Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in
writing and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii) if given by facsimile or
e-mail, then such notice shall be deemed given upon receipt of confirmation of complete transmittal or confirmation of receipt of an e-mail transmission, (iii) if
given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an
internationally recognized overnight air courier, then such notice shall be deemed given one Business Day after delivery to such carrier. 

  
 24 












 
All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days’ advance written notice to the other
party: 
 If to the Company: 

RAPT Therapeutics, Inc. 
 561
Eccles Avenue 
 South San Francisco, California 94080 

Attention: Chief Financial Officer 

Email: ryoung@rapt.com 
 With a
copy (which shall not constitute notice) to: 
 Cooley LLP 

Attention: Courtney M.W. Tygesson 

110 North Wacker 
 Suite 4200

 Chicago, Illinois 60606 

Email: ctygesson@cooley.com 
 If
to the Investors: 
 to the addresses set forth on the signature pages hereto. 

9.5.    Expenses. The parties hereto shall pay their own costs and expenses in connection herewith regardless of
whether the transactions contemplated hereby are consummated; it being understood that each of the Company and each Investor has relied on the advice of its own respective counsel. In the event that legal proceedings are commenced by any party to
this Agreement against another party to this Agreement in connection with this Agreement or the other Transaction Documents, the party or parties which do not prevail in such proceedings shall severally, but not jointly, pay their pro rata share of
the reasonable attorneys’ fees and other reasonable documented out-of-pocket costs and expenses incurred by the prevailing party in such proceedings. 

9.6.    Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and (a) prior to the Closing, Investors that agreed to purchase a majority of the Pre-Funded Warrants to be issued and sold pursuant to this Agreement and (b) following the Closing, the Required Investors. Notwithstanding the foregoing, this Agreement may not be amended and the observance of
any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor unless such amendment or waiver applies to all Investors in the same fashion. Any amendment or waiver effected in accordance with
this paragraph shall be binding upon (i) prior to Closing, each Investor and (ii) following the Closing, each holder of any Pre-Funded Warrants purchased under this Agreement or Warrant Shares at the
time outstanding, and in each case, each future holder of all such Pre-Funded Warrants and Warrant Shares and the Company. 

9.7.    Publicity. Except as set forth below, no public release or announcement concerning the transactions
contemplated hereby shall be issued by the Investors without the prior consent of the Company, except as such release or announcement may be required by law 

  
 25 












 
or the applicable rules or regulations of any securities exchange or securities market, in which case the Investors shall allow the Company reasonable time to comment on such release or
announcement in advance of such issuance. Notwithstanding the foregoing, each Investor may identify the Company and the value of such Investor’s security holdings in the Company in accordance with applicable investment reporting and disclosure
regulations or internal policies without prior notice to or consent from the Company (including, for the avoidance of doubt, filings pursuant to Sections 13 and 16 of the 1934 Act). By 8:30 a.m. (New York City time) on the Business Day immediately
following the date this Agreement is executed, the Company shall issue a press release or file a Current Report on Form 8-K disclosing all material terms of the sale of the
Pre-Funded Warrants to the Investors pursuant to this Agreement (the “Public Disclosure”). In addition, the Company will make such other filings and notices in the manner and time required by
the SEC or Nasdaq. The Company shall not include the name of any Investor in the Public Disclosure or any other public announcement without the prior written consent of such Investor, except as otherwise required by law, rule, regulation or
applicable SEC guidance. From and after the issuance of the Public Disclosure, no Investor shall be in possession of any material non-public information received from the Company or any of their respective
officers, directors, employees or agents in connection with the transactions contemplated by this Agreement. 

9.8.    Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction
shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent
permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by applicable law, the parties hereby waive
any provision of law which renders any provision hereof prohibited or unenforceable in any respect. 
 9.9.    Entire
Agreement. This Agreement, including the signature pages, Exhibits, and the other Transaction Documents constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof. 

9.10.    Further Assurances. The parties shall execute and deliver all such further instruments and documents and
take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained. 

9.11.    Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and
construed in accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York
located in New York County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby.
Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the 

  
 26 












 
same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or
proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action
or proceeding brought in any such court has been brought in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN
CONSULTED SPECIFICALLY AS TO THIS WAIVER. 
 9.12.    Independent Nature of Investors’ Obligations and
Rights. The obligations of each Investor under any Transaction Document are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other
Investor under any Transaction Document. The decision of each Investor to purchase Pre-Funded Warrants pursuant to the Transaction Documents has been made by such Investor independently of any other Investor.
Nothing contained herein or in any Transaction Document, and no action taken by any Investor pursuant thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a
presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Investor acknowledges that no other Investor has acted as agent for
such Investor in connection with making its investment hereunder and that no Investor will be acting as agent of such Investor in connection with monitoring its investment in the Pre-Funded Warrants or
enforcing its rights under the Transaction Documents. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents,
and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company acknowledges that each of the Investors has been provided with the same Transaction Documents for the purpose of
closing a transaction with multiple Investors and not because it was required or requested to do so by any Investor. 

9.13.    Limitation of Liability. Notwithstanding anything herein to the contrary, the Company acknowledges and
agrees that the liability of an Investor arising directly or indirectly under any Transaction Document of any and every nature whatsoever shall be satisfied solely out of the assets of such Investor and that no trustee, officer, other investment
vehicle or any other Affiliate of such Investor or any investor, shareholder or holder of shares of beneficial interest of such Investor shall be personally liable for any liabilities of such Investor. 

[remainder of page intentionally left blank] 

  
 27 












 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first above written. 
  

							
	COMPANY:	 		 	RAPT THERAPEUTICS, INC.
				
		 		 	By:	 	 /s/ Rodney
Young                    

		 		 		 	Name: Rodney Young
		 		 		 	Title:   Chief Financial Officer


  
 [Signature page to
Securities Purchase Agreement] 













							
	INVESTOR:	 		 	REDMILE BIOPHARMA INVESTMENTS III, L.P.
				
		 		 		 	By: Redmile Biopharma Investments III (GP), LLC, its general partner
				
		 		 		 	  

				
		 		 	By:	 	 /s/ Josh
Garcia                                        


		 		 		 	 Name: Josh Garcia
 Title:   Chief
Financial Officer



  
 [Signature page to
Securities Purchase Agreement] 












 EXHIBIT A 

Schedule of Investors 
  

									
	 Investor Name, Address

and
Residency               
	  	Number of Warrant Shares
Underlying Pre-Funded
Warrant	 	  	Aggregate Purchase Price of
Pre-Funded Warrant	 
	 Redmile Biopharma Investments III, L.P., a Delaware limited partnership

 
 One Letterman Drive, Suite D3-300
 The Presidio, San Francisco, CA 94129
	  	 	4,000,000	 	  	$	49,999,600	 












 EXHIBIT B 

Form of Pre-Funded Warrant 

[Form of Pre-Funded Warrant separately filed] 











 EXHIBIT C 

Registration Rights Agreement 

[Registration Rights Agreement separately filed] 











 EXHIBIT D 

Form of Investor Questionnaire 
  

RAPT THERAPEUTICS, INC. 

PURCHASER QUESTIONNAIRE 

This Questionnaire is being distributed to certain individuals and entities which may be offered the opportunity to purchase securities (the
“Securities”) of RAPT Therapeutics, Inc., a Delaware corporation (the “Company”). The purpose of this Questionnaire is to assure the Company that all such offers and purchases will meet the standards imposed by the Securities Act
of 1933, as amended (the “Act”), and applicable state securities laws. 
 In connection with the proposed sale of the Securities
and the preparation of the resale Registration Statement on Form S-3, please provide us with the following information. All answers will be kept confidential. However, by signing this Questionnaire, the
undersigned agrees that this information may be provided by the Company to its legal and financial advisors (including Cooley LLP), and the Company and such advisors may rely on the information set forth in this Questionnaire for purposes of
complying with all applicable securities laws and may present this Questionnaire to such parties as it reasonably deems appropriate if called upon to establish its compliance with such securities laws. The undersigned represents that the information
contained herein is complete and accurate and will notify the Company of any material change in any of such information prior to the undersigned’s investment in the Company. 

Please complete, sign, date and return one copy of this Questionnaire to Heather Sanborn of Cooley LLP, the Company’s legal
counsel, via email (hsanborn@cooley.com). 
  

	A.	 GENERAL INFORMATION 



1.    Please state your organization’s name exactly as it should appear in the Registration Statement and your
organization’s contact information: 
  

					
	Name:	 	
                 
                    
	 	
		
	Address:	 	
	  
	 	
	  
	 	
			
	Phone:	 	
                 
    
	 	
			
	Email:	 	
                 
    
	 	


 2.    Have you or your organization had any position, office or other
material relationship within the past three years with RAPT Therapeutics, Inc. (the “Company”) or its affiliates? 

☐  Yes    ☐  No 

If yes, please indicate the nature of any such relationships below: 
  

 
  

 












	B.	 ACCREDITED INVESTOR STATUS 



 

FOR INDIVIDUAL INVESTORS 


Accredited Investor Certification. The undersigned makes one of the following representations regarding its income, net worth, status as a “family
client” of a “family office,” and/or certain professional certifications or designations and certain related matters and has checked the applicable representation: 

 

	 	☐	 The undersigned’s incomei during each of the last two
years exceeded $200,000 or, if the undersigned is married or has a spousal equivalent1, the joint income of the undersigned and the undersigned’s spouse or
spousal equivalent, as applicable, during each of the last two years exceed $300,000, and the undersigned reasonably expects the undersigned’s income, from all sources during this year, will exceed $200,000 or, if the undersigned is married or
has a spousal equivalent, the joint income of undersigned and the undersigned’s spouse or spousal equivalent, as applicable, from all sources during this year will exceed $300,000. 



 

	 	☐	 The undersigned’s net worth,ii including the net
worth of the undersigned’s spouse or spousal equivalent, as applicable, is in excess of $1,000,000 (excluding the value of the undersigned’s primary residence). 



 

	 	☐	 The undersigned is a holder in good standing of one or more of the following certifications or designations
administered by the Financial Industry Regulatory Authority, Inc. (FINRA): the Licensed General Securities Representative (Series 7), Licensed Investment Adviser Representative (Series 65), or Licensed Private Securities Offerings Representative
(Series 82). 


  

	 	☐	 The undersigned is a “family client,” as defined in rule
202(a)(11)(G)-1 under the Investment Advisers Act of 1940, as amended (the “Advisers Act”), of a family office as defined in rule 202(a)(11)(G)-1
under the Advisers Act, (i) with assets under management in excess of $5,000,000, (ii) that is not formed for the specific purpose of acquiring the securities offered, and (iii) whose prospective investment is directed by a person who has
such knowledge and experience in financial and business matters that such family office is capable of evaluating the merits and risks of the prospective investment, and whose prospective investment is directed by such family office pursuant to
clause (iii) of this sentence. 


  

	 	☐	 The undersigned cannot make any of the representations set forth above. 



 
  

	1	 For purposes of this Questionnaire, “spousal equivalent” means a cohabitant occupying a relationship
generally equivalent to that of a spouse. 













 
FOR ENTITY INVESTORS 


Accredited Investor Certification. The undersigned makes one of the following representations regarding its net worth and certain related matters
and has checked the applicable representation: 
  

	 	☐	 The undersigned is a trust with total assets in excess of $5,000,000 whose purchase is directed by a person
with such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of the prospective investment. 



 

	 	☐	 The undersigned is a bank, an investment adviser registered pursuant to Section 203 of the Advisers Act or
registered pursuant to the laws of a state, any investment adviser relying on the exemption from registering with the SEC under Section 203(l) or (m) of the Advisers Act, an insurance company, an investment company registered under the
United States Investment Company Act of 1940, as amended, a broker or dealer registered pursuant to Section 15 of the United States Securities Exchange Act of 1934, as amended, a business development company, a Small Business Investment Company
licensed by the United States Small Business Administration, a Rural Business Investment Company as defined in Section 384A of the Consolidated Farm and Rural Development Act, as amended, a plan with total assets in excess of $5,000,000
established and maintained by a state for the benefit of its employees, or a private business development company as defined in Section 202(a)(22) of the Advisers Act. 



 

	 	☐	 The undersigned is an employee benefit plan and either all investment decisions are made by a bank,
savings and loan association, insurance company, or registered investment advisor, or the undersigned has total assets in excess of $5,000,000 or, if such plan is a self-directed plan, investment decisions are made solely by persons
who are accredited investors. 


  

	 	☐	 The undersigned is a corporation, limited liability company, partnership, business trust, not formed for the
purpose of acquiring the Securities, or an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the “Code”), in each case with total assets in excess of $5,000,000.



  

	 	☐	 The undersigned is an entity in which all of the equity owners (in the case of a revocable living trust,
its grantor(s)) qualify under any of the above subparagraphs, or, if an individual, each such individual has a net worth,2 either individually or upon a joint basis with such individual’s
spouse or spousal equivalent, as applicable, in excess of $1,000,000 (within the meaning of such terms as used in the definition of “accredited investor” contained in Rule 501 under the Act), or has had an individual
income1 in excess of $200,000 for each of the two most recent years, or a joint income with such individual’s spouse or spousal equivalent, as applicable, in excess of $300,000 in each of
those years, and has a reasonable expectation of reaching the same income level in the current year. 


  

	 	☐	 The undersigned is an entity, of a type not listed in any of the paragraphs above, which was not formed for the
specific purpose of acquiring the securities offered, owning investments in excess of $5,000,000. 














	 	☐	 The undersigned is a “family office,” as defined in rule
202(a)(11)(G)-1 under the Advisers Act, (i) with assets under management in excess of $5,000,000, (ii) that is not formed for the specific purpose of acquiring the securities offered, and (iii) whose
prospective investment is directed by a person who has such knowledge and experience in financial and business matters that such family office is capable of evaluating the merits and risks of the prospective investment. 



 

	 	☐	 The undersigned is a “family client,” as defined in rule
202(a)(11)(G)-1 under the Advisers Act, of a family office meeting the requirements in the above paragraph and whose prospective investment is directed by such family office pursuant to clause (iii) of
the above paragraph. 


  

	 	☐	 The undersigned cannot make any of the representations set forth above. 



 

	C.	 BENEFICIAL OWNERSHIP 



Please fill in all blanks in the following questions related to your beneficial ownership of the Company’s capital
stock. Generally, the term “beneficial ownership” refers to any direct or indirect interest in the securities which entitles you to any of the rights or benefits of ownership, even though you may not be the holder of record
of the securities. For example, securities held in “street name” over which you exercise voting or investment power would be considered beneficially owned by you. Another example of indirect ownership include ownership by a
partnership in which you are a partner. 

 


 PLEASE NOTE: IF YOU
HAVE ANY REASON TO BELIEVE THAT ANY INTEREST IN SECURITIES OF THE
COMPANY WHICH YOU MAY HAVE, HOWEVER REMOTE, IS A BENEFICIAL INTEREST,
PLEASE DESCRIBE SUCH INTEREST. FOR PURPOSES OF RESPONDING TO THIS QUESTIONNAIRE,
IT IS PREFERABLE TO ERR ON THE SIDE OF INCLUSION RATHER THAN
EXCLUSION. WHERE THE SEC’S INTERPRETATION OF BENEFICIAL OWNERSHIP
WOULD REQUIRE DISCLOSURE OF YOUR INTEREST OR POSSIBLE INTEREST IN CERTAIN
SECURITIES OF THE COMPANY, AND YOU BELIEVE THAT YOU DO NOT ACTUALLY
POSSESS THE ATTRIBUTES OF BENEFICIAL OWNERSHIP, AN APPROPRIATE RESPONSE IS TO
DISCLOSE THE INTEREST AND AT THE SAME TIME DISCLAIM BENEFICIAL OWNERSHIP
OF THE SECURITIES (SPACE IF PROVED TO DISCLAIM BENEFICIAL OWNERSHIP AT THE END OF 3 BELOW). 



1.    As of MAY 1, 2022, the undersigned owned
outright (including shares registered in the undersigned’s name individually or jointly with others, shares held in the name of a bank, broker, nominee, depository or in “street name” for my account), the following number of shares of
the Company’s capital stock (none indicated by “0”):                     . 

2.    In addition to the number of shares the undersigned owns outright as indicated by the undersigned’s
answer to question B(1), as of MAY 1, 2022, the undersigned had or shared voting power or investment power, directly or indirectly, through a contract, arrangement, understanding,
relationship or otherwise (e.g., shares held in a trust for which you are a trustee, shares subject to a written voting or investment arrangement, shares held by a corporate benefit plan over which you exercise control), over the
following number of shares of the Company’s capital stock (none indicated by “0”):                     . 











 If the answer to this question B(2) was not “0,” please provide the following
information: 
  

	 	(i)	 Number of shares with sole voting power:
                     


  

	 	(ii)	 Number of shares with shared voting power, with whom shared, and the nature of the relationship and any
underlying voting trust agreement (including the duration of the agreement, the names and addresses of the voting trustees and a brief description of the voting rights and other powers of such trustees), investment arrangement or the like:



  

													
	 SHARED VOTING
POWER
	 
	 Title of Class
	  	Number of Shares	 	  	With Whom Shared	 	  	Nature of Relationship	 
	     
	  				  				  			
	     
	  				  				  			

  

	 	(i)	 Number of shares with sole investment power:
                     


  

	 	(ii)	 Number of shares with shared investment power, with whom that power is shared; and the nature of the
relationship and any underlying voting trust agreement, investment arrangement or the like: 


  

													
	 SHARED
INVESTMENT POWER
	 
	 Title of Class
	  	Number of Shares	 	  	With Whom Shared	 	  	Nature of Relationship	 
	     
	  				  				  			
	     
	  				  				  			

 If you wish to disclaim beneficial ownership of any of the shares described in question B.2 above for purposes
other than for use in the Registration Statement, please indicate the number and class of shares being disclaimed and the reason therefore: 

3.    As of JUNE 30, 2022, the undersigned has the
right to acquire                  shares of the Company’s Common Stock pursuant to outstanding stock options issued under the Company’s stock
option plans and                  shares of capital stock pursuant to the exercise of outstanding warrants. 

 

	 	(i)	 Correct            ☐



  

	 	(ii)	 Not correct      ☐
        Describe: 













 4.    In addition to the number of shares described in my answer
to question B.3 above, as of JUNE 30, 2022, the undersigned will have the right to acquire indirectly, or to acquire “voting power” and/or “investment
power” with respect to,                  shares of the Company’s Common Stock, including, but not limited to, any right to acquire shares
(1) upon the exercise of any option, warrant, stock appreciation right or other exercisable stock right (excluding shares described in B.3 above); (2) in settlement of any stock unit award, stock bonus award or other equity award; (3) upon
conversion of a security; (4) pursuant to the power to revoke a trust, discretionary account or similar arrangement; or (5) pursuant to the automatic termination of a trust, discretionary account or similar
arrangement (none, indicated by “0” above). 
  

	 	(i)	 Correct            ☐



  

	 	(ii)	 Not correct      ☐
        Describe: 


 5.    Please identify the natural
person or persons who have voting and/or investment control over the Company’s securities that you own, and state whether such person(s) disclaims beneficial ownership of the securities. For example, if you are a general partnership, please
identify the general partners in the partnership. 
  
  

 
  











 The answers to the foregoing questions are correctly stated to the best of my information and belief. I
shall advise Heather Sanborn at (312) 881-6624 or hsanborn@cooley.com of Cooley LLP, the Company’s outside counsel, promptly of any changes in the foregoing information prior to the effectiveness of the
Registration Statement. 
  

			
	  
 (Print name of
Purchaser)

	
	  

	(Signature)
		
	By:	 	
                     
                    

	(Name and title of signatory, if Purchaser is an entity)
	
	  



 (Date) 
  

 

	i	 For purposes of this Questionnaire, “income” means adjusted gross income, as reported
for federal income tax purposes, increased by the following amounts: (a) the amount of any tax exempt interest income received, (b) the amount of losses claimed as a limited partner in a limited partnership, (c) any deduction claimed
for depletion, (d) amounts contributed to an IRA or Keogh retirement plan, (e) alimony paid, and (f) any amounts by which income from long-term capital gains has been reduced in arriving at adjusted gross income pursuant to the
provisions of Section 1202 of the Code. 



	ii	 For purposes of this Questionnaire, “net worth” means the excess of total assets,
excluding your primary residence, at fair market value over total liabilities, including your mortgage or any other liability secured by your primary residence only if and to the extent that it exceeds the value of your primary residence. Net worth
should include the value of any other shares of stock or options held by you and your spouse or spousal equivalent and any personal property owned by you or your spouse or spousal equivalent (e.g. furniture, jewelry, other valuables, etc.).
For the purposes of calculating joint net worth: joint net worth can be the aggregate net worth of you and your spouse or spousal equivalent; assets need not be held jointly to be included in the calculation.